{
    "2021-10-21": [
        [
            {
                "time": "",
                "original_text": "【权益变动】泰格医药(03347.HK)获贝莱德增持3.31万股",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "贝莱德",
                        "增持"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "恒指收跌0.45%，地产、金融逆势走强",
                "features": {
                    "keywords": [
                        "恒指",
                        "收跌",
                        "地产",
                        "金融",
                        "走强"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "地产",
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【异动股】泰格医药(03347.HK)跌3.33%",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "跌"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "干货！2021年中国医药研发外包(CRO)行业龙头企业分析——药明康德：行业中的“领军者”",
                "features": {
                    "keywords": [
                        "医药研发外包",
                        "CRO",
                        "药明康德",
                        "龙头企业"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}